Endoplasmic Reticulum Stress and Destruction of Pancreatic β Cells in Type 1 Diabetes

0
0
0

Endoplasmic Reticulum Stress and Destruction of Pancreatic β Cells in Type 1 Diabetes

Type 1 diabetes (T1D) is an autoimmune disorder characterized by the progressive destruction of insulin-producing pancreatic β cells, leading to insulin deficiency and hyperglycemia. While genetic predisposition plays a role in T1D development, environmental factors such as viral infections, oxidative stress, chemical exposure, and chronic inflammation significantly contribute to disease onset. Recent research highlights endoplasmic reticulum (ER) stress as a critical mediator of β cell dysfunction and death in T1D. This article examines the mechanisms by which ER stress drives β cell destruction, the interplay between ER stress and autoimmune processes, and potential therapeutic strategies targeting ER pathways.

Endoplasmic Reticulum Stress and the Unfolded Protein Response

Pancreatic β cells possess a highly developed ER network to manage the substantial demand for insulin synthesis, folding, and secretion. Under physiological conditions, the ER maintains protein quality control through the unfolded protein response (UPR), a conserved signaling cascade activated during ER stress. The UPR is mediated by three ER transmembrane sensors: protein kinase RNA-like ER kinase (PERK), inositol-requiring enzyme 1α (IRE1α), and activating transcription factor 6 (ATF6).

  1. PERK Pathway:
    Upon ER stress, PERK phosphorylates eukaryotic translation initiation factor 2α (eIF2α), transiently inhibiting global protein synthesis to reduce ER workload. Concurrently, selective translation of activating transcription factor 4 (ATF4) occurs, promoting genes involved in amino acid metabolism and antioxidant responses. However, prolonged PERK activation induces C/EBP homologous protein (CHOP), a pro-apoptotic transcription factor.

  2. IRE1α Pathway:
    IRE1α exhibits dual kinase and endoribonuclease activity. It splices X-box binding protein 1 (XBP1) mRNA to produce spliced XBP1 (sXBP1), a transcription factor that enhances ER folding capacity and degradation of misfolded proteins. Under severe stress, IRE1α recruits apoptosis signal-regulating kinase 1 (ASK1) and TNF receptor-associated factor 2 (TRAF2), activating c-Jun N-terminal kinase (JNK) and caspase-12, which drive apoptosis.

  3. ATF6 Pathway:
    ER stress triggers ATF6 translocation to the Golgi apparatus, where it is cleaved to release its active form (ATF6N). ATF6N upregulates chaperones like glucose-regulated protein 78 (GRP78) and genes involved in ER-associated degradation (ERAD). However, chronic ATF6 activation also promotes CHOP and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), linking ER stress to inflammation and cell death.

Under mild ER stress, the UPR restores homeostasis by reducing protein load, enhancing folding capacity, and degrading misfolded proteins. However, unresolved ER stress shifts the UPR from adaptive to pro-apoptotic signaling, culminating in β cell loss.

ER Stress in Type 1 Diabetes: Experimental Evidence

Cellular Models

Studies using β cell lines (e.g., INS-1E, Min6) demonstrate that cytokines central to T1D pathogenesis, such as interleukin-1β (IL-1β) and interferon-γ (IFN-γ), induce ER stress markers, including GRP78 membrane translocation and PERK-eIF2α-CHOP pathway activation. For instance, siRNA-mediated silencing of CHOP in high glucose-treated β cells significantly reduces apoptosis, underscoring CHOP’s role in stress-induced cell death. Similarly, ATF6α knockdown in INS-1 cells activates JNK and p38 MAPK pathways, exacerbating apoptosis, while pharmacological inhibition of these kinases rescues cell viability.

Animal Models

Genetic models highlight the importance of UPR components in β cell survival:

  • PERK knockout mice develop neonatal diabetes due to β cell failure, characterized by hypoinsulinemia, hyperglycemia, and ER dilation.
  • eIF2α Ser51Ala mutant mice exhibit severe β cell defects, leading to perinatal death from hypoglycemia.
  • IRE1α-deficient mice display hyperglycemia, hypoinsulinemia, and exocrine pancreas abnormalities.

In non-obese diabetic (NOD) mice, a T1D model, islets show upregulated ER stress markers (e.g., GRP78, CHOP), structural ER abnormalities, and NF-κB activation. These findings align with human studies showing ER stress in pancreatic tissues from T1D patients.

Human Studies

Mutations in ER-related genes are linked to diabetes:

  • PERK mutations cause Wolcott-Rallison syndrome, characterized by neonatal diabetes and ER dysfunction.
  • WFS1 mutations, associated with Wolfram syndrome, impair ER stress mitigation, leading to β cell apoptosis.
  • A novel Insulin (INS) gene mutation (L35Q) disrupts disulfide bond formation, inducing proinsulin misfolding and ER stress in neonatal diabetes.

These genetic insights confirm that ER homeostasis is critical for β cell survival and function.

Mechanisms Linking ER Stress to T1D Pathogenesis

ER Stress and Inflammation

Chronic ER stress amplifies inflammatory responses through UPR pathways:

  • IRE1α-TRAF2-ASK1 and PERK-CHOP activate JNK and NF-κB, increasing pro-inflammatory cytokines (IL-6, TNF-α, IFN-γ).
  • Inflammatory cytokines reciprocally induce ER stress via reactive oxygen species (ROS) and nitric oxide (NO), which disrupt calcium homeostasis and chaperone function.

This vicious cycle creates a pro-apoptotic environment, exacerbating β cell loss.

ER Stress and Autoimmunity

ER stress may trigger autoimmunity through post-translational modifications (PTMs) of β cell proteins. Misfolded proteins like insulin, GRP78, and glutamic acid decarboxylase 65 (GAD65) can act as neoantigens. For example, oxidized insulin epitopes with disulfide bonds are recognized by CD4+ T cells in T1D patients, suggesting ER stress-induced PTMs contribute to autoimmune activation.

Therapeutic Targeting of ER Stress in T1D

Chemical Chaperones

  • 4-Phenylbutyric acid (PBA) and tauroursodeoxycholic acid (TUDCA) stabilize protein folding, reduce CHOP expression, and improve β cell function in diabetic models. Clinical trials are evaluating these agents for metabolic disorders (ClinicalTrials.gov: NCT03462940, NCT02218619).

Calcium Homeostasis Modulators

  • Dantrolene, a ryanodine receptor blocker, prevents ER calcium depletion and apoptosis in Wolfram syndrome models.

UPR Pathway Modulation

  • IRE1α kinase inhibitors (e.g., KIRA6) attenuate pro-apoptotic signaling while preserving β cell function and insulin secretion in Akita diabetic mice.
  • PERK inhibitors (e.g., GSK2606414) at low doses enhance glucose-stimulated insulin secretion (GSIS) by upregulating GRP78 and modulating calcium flux.

Natural Compounds

  • Curcumin and resveratrol mitigate ER stress via antioxidant and anti-inflammatory effects, showing promise in preclinical studies.

Gene Therapy

  • Overexpression of chaperones like GRP78 or XBP1 enhances ER folding capacity, protecting β cells from stress-induced apoptosis.

Future Directions

Key unanswered questions include:

  1. How does the UPR transition from adaptive to apoptotic signaling in T1D?
  2. Can ER stress biomarkers predict T1D onset or progression?
  3. What are the safe therapeutic windows for targeting UPR components?

Addressing these questions will advance the development of ER-targeted therapies, potentially halting β cell destruction and reversing autoimmune responses in T1D.

doi.org/10.1097/CM9.0000000000000583

Was this helpful?

0 / 0